Pharmacogenomics tests in Dubai & UAE

Compare available Pharmacogenomics tests, their listed prices and the information provided for each option. Test selection and preparation should be discussed with your clinician.

Tests in this category

Listed price range

700.00–4,700.00 AED

Clinical preparation

Confirm test-specific instructions with your clinician or laboratory.

Compare available tests

Pharmacogenomics test prices

Showing 1–14 of 14 matching tests.

Pharmacogenomics diagnostic tests, details, and listed prices
Test and description	Specimen	Typical duration	Price	Options
TEST-86 5-Fluorouracil (5-FU) Toxicity Test This test evaluates the DPYD gene for variants associated with reduced 5-Fluorouracil metabolism and increased risk of severe toxicity.	4 mL Whole Blood (Lavender-top EDTA)	5–7 working days	1,500.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["DPYD gene variants", "5-Fluorouracil metabolism capacity"] Parameters [] Preparation ["No specific fasting required", "No medication or diet restrictions"] Indications ["Patients scheduled for 5-Fluorouracil chemotherapy", "Colorectal cancer", "Breast cancer", "Head/neck cancer"] Measurement technique Confirm with laboratory Codes LOINC: 92730-6 ICD-10: Z01.89, Z15.89, Z79.899 Clinical summary This test evaluates the DPYD gene for variants associated with reduced 5-Fluorouracil metabolism and increased risk of severe toxicity.
TEST-6121 ABCB1 Gene Colchicine Resistance Genetic Test This genetic test evaluates variants in the ABCB1 gene that influence an individual's response to colchicine medication.	Peripheral whole blood	3 to 4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["ABCB1 gene variants", "Colchicine transport efficiency"] Parameters [] Preparation [] Indications ["Patients with gout or Familial Mediterranean Fever experiencing suboptimal colchicine efficacy.", "Personalized colchicine dosing guidance."] Measurement technique Confirm with laboratory Codes LOINC: 81616-3 ICD-10: Z13.89 Clinical summary This genetic test evaluates variants in the ABCB1 gene that influence an individual's response to colchicine medication.
TEST-117 ADRB2 Genotyping for Beta‑2 Agonist Responsiveness Test This test evaluates genetic variations in the ADRB2 gene to predict responsiveness to beta-2 agonist bronchodilators.	Peripheral Whole Blood (EDTA lavender-top tube)	10 working days	750.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["ADRB2 gene variants (e.g., Arg16Gly, Gln27Glu)", "Predicted response to beta-2 agonists"] Parameters [] Preparation ["No special preparation required", "Continue all medications as prescribed"] Indications ["Optimising beta-2 agonist therapy", "Personalised management of asthma", "Personalised management of COPD"] Measurement technique Confirm with laboratory Codes LOINC: 21636-6 ICD-10: J45.9 Clinical summary This test evaluates genetic variations in the ADRB2 gene to predict responsiveness to beta-2 agonist bronchodilators.
TEST-697 COMT Genotyping Test The COMT Genotyping test evaluates genetic variants in the catechol-O-methyltransferase gene to guide personalized medication dosing.	Peripheral Whole Blood (Lavender-top EDTA)	10 working days (sample received by 11 am)	4,700.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Catechol-O-methyltransferase (COMT) gene variants", "Single nucleotide polymorphisms (SNPs) within the COMT gene"] Parameters [] Preparation ["No special fasting is required."] Indications ["Guiding personalized medication dosing for psychiatric therapies", "Guiding personalized medication dosing for pain management therapies", "Optimizing treatment for conditions involving catecholamine neurotransmitters"] Measurement technique Confirm with laboratory Codes LOINC: 94436-2 ICD-10: Z13.89 Clinical summary The COMT Genotyping test evaluates genetic variants in the catechol-O-methyltransferase gene to guide personalized medication dosing.
TEST-6352 CYP2B6 Pharmacogenomic Test (Efavirenz Metabolism) This test evaluates genetic variants in the CYP2B6 gene that affect the metabolism of the antiretroviral drug efavirenz.	Peripheral Whole Blood	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["CYP2B6 gene variants (6, 18)", "Efavirenz metabolism rate"] Parameters [] Preparation ["No specific fasting required", "Inform phlebotomist of all current medications"] Indications ["Patients starting efavirenz therapy", "Patients experiencing adverse effects on efavirenz", "Personalized HIV treatment optimization"] Measurement technique Confirm with laboratory Codes LOINC: 83909-6 ICD-10: Z13.83 Clinical summary This test evaluates genetic variants in the CYP2B6 gene that affect the metabolism of the antiretroviral drug efavirenz.
TEST-6286 CYP2C9 Gene Warfarin Resistance Genetic Test This test evaluates genetic variants within the CYP2C9 gene that impact the metabolism of warfarin and related anticoagulants.	Peripheral Whole Blood	21 to 28 Working Days	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["CYP2C9 gene variants", "Warfarin metaboliser phenotype"] Parameters [] Preparation ["Mandatory pre-test genetic counselling session", "No fasting required unless advised by physician", "No medication changes required unless advised by physician"] Indications ["Before initiating warfarin therapy", "Unexplained resistance or sensitivity to warfarin", "Patients with bleeding complications or therapeutic failure on warfarin", "Patients on polypharmacy affecting warfarin metabolism"] Measurement technique Confirm with laboratory Codes LOINC: 74525-7 ICD-10: Z13.71, Z13.858 Clinical summary This test evaluates genetic variants within the CYP2C9 gene that impact the metabolism of warfarin and related anticoagulants.
TEST-925 CYP3A422 Genotyping Test This test identifies the presence or absence of the CYP3A422 variant (rs35599367), a genetic polymorphism associated with reduced CYP3A4 enzyme activity.	Whole Blood (Peripheral, EDTA Tube)	10 Working Days	1,500.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["CYP3A422 variant (rs35599367)", "CYP3A4 enzyme activity prediction"] Parameters [{"name": "CYP3A422 Genotype", "reference_range": "Homozygous Wild-Type, Heterozygous, Homozygous Variant"}] Preparation ["No fasting required", "No special diet required", "Complete Genomics Clinical Information Requisition Form (Form 20)"] Indications ["Personalized dosing of CYP3A4 substrates (e.g., statins, tacrolimus, calcium channel blockers)", "Predicting risk of drug toxicity or inefficacy", "Guiding medication selection"] Measurement technique Confirm with laboratory Codes LOINC: 81307-7 ICD-10: Z13.89 Clinical summary This test identifies the presence or absence of the CYP3A4*22 variant (rs35599367), a genetic polymorphism associated with reduced CYP3A4 enzyme activity.
TEST-1667 Cytochrome P450 2D6 (CYP2D6) Genotyping Test This test evaluates genetic variations in the CYP2D6 gene, predicting how an individual metabolizes drugs processed by this enzyme.	Whole Blood (peripheral)	10–12 working days	900.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["CYP2D6 gene variants", "Metaboliser phenotype (poor, intermediate, extensive, ultra-rapid)"] Parameters [] Preparation ["No fasting required", "Valid doctor’s prescription needed (unless for surgery, pregnancy, or travel)"] Indications ["Personalized therapy for tamoxifen", "Personalized therapy for antidepressants", "Personalized therapy for opioids", "Adverse drug reactions to CYP2D6 substrates"] Measurement technique Confirm with laboratory Codes LOINC: 81856-6 ICD-10: Z13.89 Clinical summary This test evaluates genetic variations in the CYP2D6 gene, predicting how an individual metabolizes drugs processed by this enzyme.
TEST-22 DPYD Gene Mutation (5-FU Toxicity Risk) Detection Test This test evaluates for specific genetic variants in the DPYD gene associated with reduced DPD enzyme activity and increased risk of severe toxicity from fluoropyrimidine chemother...	Whole Blood – Lavender Top (EDTA) – 4 mL	12-15 Working Days	1,100.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["DPYD gene variants (2A, 13, rs67376798)", "DPD enzyme activity risk"] Parameters [] Preparation [] Indications ["Patients prescribed fluoropyrimidine chemotherapy (5-FU, capecitabine)", "Risk stratification for chemotherapy toxicity"] Measurement technique Confirm with laboratory Codes LOINC: 79714-6 ICD-10: Z01.812 Clinical summary This test evaluates for specific genetic variants in the DPYD gene associated with reduced DPD enzyme activity and increased risk of severe toxicity from fluoropyrimidine chemotherapy.
TEST-1880 DPYD Genotyping for 5-Fluorouracil (5-FU) Toxicity & Chemotherapeutic Response Test This test identifies genetic variants in the DPYD gene associated with reduced enzyme activity, predicting increased risk of severe toxicity from 5-FU chemotherapy.	Peripheral whole blood	3–4 business days	700.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["DPYD gene variants (2A, 13, rs67376798)", "DPYDPhenotype (Normal, Intermediate, Poor Metaboliser)"] Parameters [] Preparation ["No fasting required", "No special preparation needed"] Indications ["Pre-treatment screening before 5-FU or capecitabine therapy", "Personalized chemotherapy dosing"] Measurement technique Confirm with laboratory Codes LOINC: 81224-6 ICD-10: Z13.79, Z51.11, T45.1X5A Clinical summary This test identifies genetic variants in the DPYD gene associated with reduced enzyme activity, predicting increased risk of severe toxicity from 5-FU chemotherapy.
TEST-3329 TPMT Genotyping Test This test evaluates genetic variations in the TPMT gene, which influence the activity of the thiopurine methyltransferase enzyme.	Whole blood (EDTA tube)	3 working days	900.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["TPMT gene variants", "Thiopurine methyltransferase enzyme activity prediction"] Parameters [] Preparation ["No specific fasting required", "Inform lab of any recent blood transfusions (within 4 weeks)"] Indications ["Predicting thiopurine drug toxicity risk", "Guiding thiopurine dose adjustments", "Patients with oncology, gastroenterology, or autoimmune diseases requiring thiopurines"] Measurement technique Confirm with laboratory Codes LOINC: 37011-6 ICD-10: Z13.89 Clinical summary This test evaluates genetic variations in the TPMT gene, which influence the activity of the thiopurine methyltransferase enzyme.
TEST-3369 UGT1A1 Gene Polymorphism (TA Repeat) Detection Test This test evaluates the number of TA repeats in the UGT1A1 gene promoter, identifying genetic variations associated with drug metabolism and bilirubin clearance.	Peripheral Whole Blood (EDTA)	7 Working Days	1,200.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Number of TA dinucleotide repeats in the UGT1A1 gene promoter", "UGT1A1 gene alleles (e.g., (TA)6, (TA)7)"] Parameters [] Preparation ["No fasting required", "No medication changes required", "Provide a 4 mL whole blood sample in an EDTA tube", "Keep sample refrigerated but never frozen"] Indications ["Predicting severe irinotecan toxicity", "Confirming Gilbert syndrome", "Personalized chemotherapy dosing"] Measurement technique Confirm with laboratory Codes LOINC: 21622-0 ICD-10: Z13.89 Clinical summary This test evaluates the number of TA repeats in the UGT1A1 gene promoter, identifying genetic variations associated with drug metabolism and bilirubin clearance.
TEST-6188 VKORC1 Gene Coumarin Resistance Genetic Test This test evaluates genetic variants in the VKORC1 gene that affect sensitivity to coumarin anticoagulants like warfarin.	Peripheral whole blood (3–5 mL in EDTA tube), extracted DNA, or FTA card blood spot	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["VKORC1 gene variants", "Coumarin anticoagulant sensitivity"] Parameters [] Preparation ["No specific preparation required", "Do not stop warfarin prior to sample collection"] Indications ["Patients requiring long-term anticoagulation", "History of coumarin resistance", "Adverse reactions to standard warfarin dosing"] Measurement technique Confirm with laboratory Codes LOINC: 93957-5 ICD-10: Z13.89, Z79.01 Clinical summary This test evaluates genetic variants in the VKORC1 gene that affect sensitivity to coumarin anticoagulants like warfarin.
TEST-3443 Warfarin Sensitivity Detection Test (CYP2C9 & VKORC1 Genotyping) This test evaluates genetic variants in the CYP2C9 and VKORC1 genes that influence an individual's response to warfarin.	Whole Blood (EDTA)	13 Calendar Days	2,500.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["CYP2C9 gene variants (2, 3 alleles)", "VKORC1 gene variant (-1639G>A)"] Parameters [{"name": "CYP2C92", "reference_range": null}, {"name": "CYP2C93", "reference_range": null}, {"name": "VKORC1 -1639G>A", "reference_range": null}] Preparation ["No fasting required", "No special preparation required"] Indications ["Patients requiring warfarin therapy", "Patients with atrial fibrillation", "Patients with mechanical heart valves", "Patients with venous thromboembolism"] Measurement technique Confirm with laboratory Codes LOINC: 94477-7 ICD-10: Z13.89 Clinical summary This test evaluates genetic variants in the CYP2C9 and VKORC1 genes that influence an individual's response to warfarin.

Category overview

Pharmacogenomics: overview

Enduring the trial-and-error process of finding the right medication can be exhausting and dangerous, but precision medicine offers a tailored, highly effective alternative. As a revolutionary offering in our advanced Genetics services, Pharmacogenomics testing analyzes how your unique DNA affects your body’s ability to process and respond to specific medications. By leveraging state-of-the-art diagnostic technology, this vital genetic profiling helps your healthcare provider identify the safest, most effective drugs and dosages for your individual biology, safely guiding personalized psychiatric, cardiovascular, or pain management treatments. Trusted for clinical excellence among premier diagnostic labs in the UAE, DNA Labs ensures absolute patient confidentiality, uncompromising diagnostic precision, and prompt reporting. Take control of your medication safety—schedule your pharmacogenomics testing in UAE, arrange a seamless home sample collection, or connect with our specialized clinical team.

Before booking

Use the test details as a conversation starter

The right diagnostic option depends on your reason for testing and individual circumstances. Check the listed specimen and timing, then confirm any preparation requirements with the ordering clinician or laboratory before collection.